Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic.
Identifieur interne : 001027 ( Main/Corpus ); précédent : 001026; suivant : 001028Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic.
Auteurs : Sameeha S. Husayn ; Jeremy D. Brown ; Colby L. Presley ; Kelsey Boghean ; Jacquelyn D. WallerSource :
- Journal of pharmacy practice [ 1531-1937 ] ; 2020.
Abstract
With the emergence of a novel severe acute respiratory syndrome coronavirus, investigators worldwide are scrambling to identify appropriate treatment modalities, develop accurate testing, and produce a vaccine. To date, effective treatment remains elusive. Chloroquine phosphate and hydroxychloroquine sulfate (HCQ), well-known antimalarial drugs effective in the treatment of systemic lupus erythematosus, rheumatoid arthritis, porphyria cutanea tarda, and chronic Q fever, are currently under investigation. The United States Food and Drug Administration recently issued an Emergency Use Authorization for CQ and HCQ use in the treatment of coronavirus disease 2019 (COVID-19). With spikes in HCQ use and demand, ethical considerations encompassing appropriate use, patient autonomy, nonmaleficence, and distributive justice abound. As drug experts, pharmacists are uniquely positioned to advocate for patients with chronic conditions necessitating HCQ use, assist in the appropriate prescribing of HCQ for COVID-19, and ensure patients and health care professionals are continually educated during this public health crisis. This review highlights the worldwide pandemic, describes appropriate HCQ use for chronic conditions, highlights available alternatives, and deliberates evolving ethical questions. With assistance from colleagues, state boards of pharmacy, and national organizations, pharmacists ensure the just distribution of valuable pharmaceuticals to patients having COVID-19 while supporting the needs of patients requiring HCQ for chronic conditions.
DOI: 10.1177/0897190020942658
PubMed: 32734810
Links to Exploration step
pubmed:32734810Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic.</title><author><name sortKey="Husayn, Sameeha S" sort="Husayn, Sameeha S" uniqKey="Husayn S" first="Sameeha S" last="Husayn">Sameeha S. Husayn</name><affiliation><nlm:affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Brown, Jeremy D" sort="Brown, Jeremy D" uniqKey="Brown J" first="Jeremy D" last="Brown">Jeremy D. Brown</name><affiliation><nlm:affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Presley, Colby L" sort="Presley, Colby L" uniqKey="Presley C" first="Colby L" last="Presley">Colby L. Presley</name><affiliation><nlm:affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Boghean, Kelsey" sort="Boghean, Kelsey" uniqKey="Boghean K" first="Kelsey" last="Boghean">Kelsey Boghean</name><affiliation><nlm:affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Waller, Jacquelyn D" sort="Waller, Jacquelyn D" uniqKey="Waller J" first="Jacquelyn D" last="Waller">Jacquelyn D. Waller</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32734810</idno><idno type="pmid">32734810</idno><idno type="doi">10.1177/0897190020942658</idno><idno type="wicri:Area/Main/Corpus">001027</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001027</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic.</title><author><name sortKey="Husayn, Sameeha S" sort="Husayn, Sameeha S" uniqKey="Husayn S" first="Sameeha S" last="Husayn">Sameeha S. Husayn</name><affiliation><nlm:affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Brown, Jeremy D" sort="Brown, Jeremy D" uniqKey="Brown J" first="Jeremy D" last="Brown">Jeremy D. Brown</name><affiliation><nlm:affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Presley, Colby L" sort="Presley, Colby L" uniqKey="Presley C" first="Colby L" last="Presley">Colby L. Presley</name><affiliation><nlm:affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Boghean, Kelsey" sort="Boghean, Kelsey" uniqKey="Boghean K" first="Kelsey" last="Boghean">Kelsey Boghean</name><affiliation><nlm:affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Waller, Jacquelyn D" sort="Waller, Jacquelyn D" uniqKey="Waller J" first="Jacquelyn D" last="Waller">Jacquelyn D. Waller</name><affiliation><nlm:affiliation>Department of Biomedical Sciences, Rocky Vista University, Parker, CO, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of pharmacy practice</title><idno type="eISSN">1531-1937</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">With the emergence of a novel severe acute respiratory syndrome coronavirus, investigators worldwide are scrambling to identify appropriate treatment modalities, develop accurate testing, and produce a vaccine. To date, effective treatment remains elusive. Chloroquine phosphate and hydroxychloroquine sulfate (HCQ), well-known antimalarial drugs effective in the treatment of systemic lupus erythematosus, rheumatoid arthritis, porphyria cutanea tarda, and chronic Q fever, are currently under investigation. The United States Food and Drug Administration recently issued an Emergency Use Authorization for CQ and HCQ use in the treatment of coronavirus disease 2019 (COVID-19). With spikes in HCQ use and demand, ethical considerations encompassing appropriate use, patient autonomy, nonmaleficence, and distributive justice abound. As drug experts, pharmacists are uniquely positioned to advocate for patients with chronic conditions necessitating HCQ use, assist in the appropriate prescribing of HCQ for COVID-19, and ensure patients and health care professionals are continually educated during this public health crisis. This review highlights the worldwide pandemic, describes appropriate HCQ use for chronic conditions, highlights available alternatives, and deliberates evolving ethical questions. With assistance from colleagues, state boards of pharmacy, and national organizations, pharmacists ensure the just distribution of valuable pharmaceuticals to patients having COVID-19 while supporting the needs of patients requiring HCQ for chronic conditions.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32734810</PMID><DateRevised><Year>2020</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-1937</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Journal of pharmacy practice</Title><ISOAbbreviation>J Pharm Pract</ISOAbbreviation></Journal><ArticleTitle>Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic.</ArticleTitle><Pagination><MedlinePgn>897190020942658</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0897190020942658</ELocationID><Abstract><AbstractText>With the emergence of a novel severe acute respiratory syndrome coronavirus, investigators worldwide are scrambling to identify appropriate treatment modalities, develop accurate testing, and produce a vaccine. To date, effective treatment remains elusive. Chloroquine phosphate and hydroxychloroquine sulfate (HCQ), well-known antimalarial drugs effective in the treatment of systemic lupus erythematosus, rheumatoid arthritis, porphyria cutanea tarda, and chronic Q fever, are currently under investigation. The United States Food and Drug Administration recently issued an Emergency Use Authorization for CQ and HCQ use in the treatment of coronavirus disease 2019 (COVID-19). With spikes in HCQ use and demand, ethical considerations encompassing appropriate use, patient autonomy, nonmaleficence, and distributive justice abound. As drug experts, pharmacists are uniquely positioned to advocate for patients with chronic conditions necessitating HCQ use, assist in the appropriate prescribing of HCQ for COVID-19, and ensure patients and health care professionals are continually educated during this public health crisis. This review highlights the worldwide pandemic, describes appropriate HCQ use for chronic conditions, highlights available alternatives, and deliberates evolving ethical questions. With assistance from colleagues, state boards of pharmacy, and national organizations, pharmacists ensure the just distribution of valuable pharmaceuticals to patients having COVID-19 while supporting the needs of patients requiring HCQ for chronic conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Husayn</LastName><ForeName>Sameeha S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-6382-2210</Identifier><AffiliationInfo><Affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jeremy D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Presley</LastName><ForeName>Colby L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3646-7732</Identifier><AffiliationInfo><Affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boghean</LastName><ForeName>Kelsey</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>College of Osteopathic Medicine, Rocky Vista University, Parker, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waller</LastName><ForeName>Jacquelyn D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7467-8162</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Rocky Vista University, Parker, CO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharm Pract</MedlineTA><NlmUniqueID>8900945</NlmUniqueID><ISSNLinking>0897-1900</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">distributive justice</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">nonmaleficence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32734810</ArticleId><ArticleId IdType="doi">10.1177/0897190020942658</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001027 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001027 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32734810
|texte= Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32734810" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |